CASI Pharmaceuticals, Inc. (CASI) announced that its board of directors has received a proposal from the chairman of the company for acquiring its business operations in China. Shares of this biopharmaceutical company are soaring in pre-market trading on the news. CASI Pharmaceuticals is focused on developing and commercializing innovative drugs in China, the United States, and the rest of the world. Dr. Wei-Wu He, CASI’s chairman of the board and CEO, sent a preliminary non-binding proposal letter, dated J ...